These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 7700286)

  • 1. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.
    Cortelazzo S; Finazzi G; Ruggeri M; Vestri O; Galli M; Rodeghiero F; Barbui T
    N Engl J Med; 1995 Apr; 332(17):1132-6. PubMed ID: 7700286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of low-dose aspirin and hydroxyurea on platelet-leukocyte interactions in patients with essential thrombocythemia.
    Treliński J; Tybura M; Smolewski P; Robak T; Chojnowski K
    Blood Coagul Fibrinolysis; 2009 Dec; 20(8):646-51. PubMed ID: 19741509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
    Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial experience with dual antiplatelet thromboprophylaxis using clopidogrel and aspirin in patients with mechanical aortic prostheses.
    García-Rinaldi R; Carro-Pagán C; Schaff HV; McKellar SH; Thompson JL; Quiñones J; Rodríguez-Acosta JF
    J Heart Valve Dis; 2009 Nov; 18(6):617-25; discussion 626. PubMed ID: 20099710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
    Harrison CN; Campbell PJ; Buck G; Wheatley K; East CL; Bareford D; Wilkins BS; van der Walt JD; Reilly JT; Grigg AP; Revell P; Woodcock BE; Green AR;
    N Engl J Med; 2005 Jul; 353(1):33-45. PubMed ID: 16000354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is ticlopidine a safe alternative to aspirin for management of myeloproliferative disorders?
    Ruggeri M; Castaman G; Rodeghiero F
    Haematologica; 1993; 78(6 Suppl 2):18-21. PubMed ID: 8039753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
    Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
    Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of risk factors predicting thrombotic and/or haemorrhagic complications in 306 patients with essential thrombocythemia.
    Radaelli F; Colombi M; Calori R; Zilioli VR; Bramanti S; Iurlo A; Zanella A
    Hematol Oncol; 2007 Sep; 25(3):115-20. PubMed ID: 17464935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polycythemia vera and essential thrombocythemia in young patients.
    Frezzato M; Ruggeri M; Castaman G; Rodeghiero F
    Haematologica; 1993; 78(6 Suppl 2):11-7. PubMed ID: 8039752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Splenectomy after portal thrombosis in patients with polycythemia vera and essential thrombocythemia.
    Randi ML; Fabris F; Ruzzon E; Pacquola E; Cella G; Girolami A
    Haematologica; 2002 Nov; 87(11):1180-4. PubMed ID: 12414348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anagrelide: new drug. Essential thrombocythaemia: further evaluation needed for this last-resort treatment.
    Prescrire Int; 2006 Jun; 15(83):83-6. PubMed ID: 16764090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group.
    Hass WK; Easton JD; Adams HP; Pryse-Phillips W; Molony BA; Anderson S; Kamm B
    N Engl J Med; 1989 Aug; 321(8):501-7. PubMed ID: 2761587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
    Rose PG; Bundy BN; Watkins EB; Thigpen JT; Deppe G; Maiman MA; Clarke-Pearson DL; Insalaco S
    N Engl J Med; 1999 Apr; 340(15):1144-53. PubMed ID: 10202165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspirin and platelet-lowering agents for the prevention of vascular complications in essential thrombocythemia.
    Michiels JJ
    Clin Appl Thromb Hemost; 1999 Oct; 5(4):247-51. PubMed ID: 10726022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
    Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE
    N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    Sabatine MS; Cannon CP; Gibson CM; López-Sendón JL; Montalescot G; Theroux P; Claeys MJ; Cools F; Hill KA; Skene AM; McCabe CH; Braunwald E;
    N Engl J Med; 2005 Mar; 352(12):1179-89. PubMed ID: 15758000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
    Berger PB; Bhatt DL; Fuster V; Steg PG; Fox KA; Shao M; Brennan DM; Hacke W; Montalescot G; Steinhubl SR; Topol EJ;
    Circulation; 2010 Jun; 121(23):2575-83. PubMed ID: 20516378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy.
    Palandri F; Catani L; Testoni N; Ottaviani E; Polverelli N; Fiacchini M; De Vivo A; Salmi F; Lucchesi A; Baccarani M; Vianelli N
    Am J Hematol; 2009 Apr; 84(4):215-20. PubMed ID: 19208420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Essential thrombocythemia: a relative benign long-term course.
    Meisel S; Shpilberg O; Ramot B; Ben-Bassat I
    Isr J Med Sci; 1993 Apr; 29(4):190-4. PubMed ID: 8491569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.
    Rebulla P; Finazzi G; Marangoni F; Avvisati G; Gugliotta L; Tognoni G; Barbui T; Mandelli F; Sirchia G
    N Engl J Med; 1997 Dec; 337(26):1870-5. PubMed ID: 9407153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.